A phase 2 double blind, placebo controlled multi-center study to evaluate the efficacy and safety of Tcelna in subjects with Secondary Progressive multiple sclerosis.

• Study conducted in the United States and Canada
• 18-60 years of age with a diagnosis of Secondary Progressive multiple sclerosis
• 5 subcutaneous injections annually
• 2 year treatment period
• 180 subjects (90 Tcelna: 90 placebo)

For more information on the Abili-T trial clinical trial, including participating sites, click here or go to clinicaltrials.gov and search NCT01684761 or by Abili-T.